TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $403 to $380.
TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $403 to $380.